CHICAGO — Infliximab (multiple brands) was associated with fewer discontinuations for lack of efficacy than vedolizumab (Entyvio) during the maintenance phase of ulcerative colitis treatment, an ...
BERLIN — Ulcerative colitis (UC) patients who fail on first-line therapy appear to have better outcomes with vedolizumab (Entyvio) than with infliximab, suggests EFFICACI, the first trial directly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results